



Press release
January 7, 2015

GENOMICS | DIAGNOSTIC TESTS | GENETICS | R&D

Genomic Vision achieves major milestone with delivery of new high-throughput genome analyzer to Quest Diagnostics

- The new analyzer is designed to enable the development of future lab-developed tests for hereditary cancers and other complex diseases based on molecular combing technology
- Goal of collaboration to extend advanced cancer testing services to patients and physicians in the United States

Bagneux (France) - Genomic Vision (FR0011799907 - GV), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today announces the delivery of a major milestone of its strategic collaboration with Quest Diagnostics, the world's leading provider of diagnostic information services. Genomic Vision has delivered a high-throughput genome analyzer now operational at the Quest Diagnostics clinical laboratory in San Juan Capistrano, Calif. Under terms of the collaboration, Quest Diagnostics has the right to use the instrument to create an additional laboratory-developed test for the detection of mutations in the BRCA gene, which can cause hereditary breast and ovarian cancer, and other complex diseases. The test would potentially supplement Quest's BRCAVantage suite of BRCA test services based on next-generation sequencing.

Genomic Vision's molecular combing technology allows the fluorescent barcoding of multiple genes involved in disease development giving each target gene a specific Genetic Morse Code. The analyzer detects and identifies signature data coming from the Genetic Morse Code. It provides a multiplexed solution to detect genomic aberrations involved in complex diseases such as cancer, muscular and neuronal development disorders.

The new analyzer was developed to increase throughput of diagnostic screening volume and reduce turnaround times, for faster results reporting.

In addition to BRCA, the collaborative terms also give Quest Diagnostics the option to use the platform to accelerate the development of lab-developed tests for other hereditary cancers, such as Lynch syndrome or hereditary nonpolyposis colorectal cancer, as well as spinal muscular atrophy.

Genomic Vision and Quest Diagnostics entered into a multi-year exclusive collaboration based on Genomic Vision's proprietary molecular combing genome-analysis technology in 2010. In 2013, Quest Diagnostics introduced the first lab-developed test, for FSHD, a debilitating myopathy, based on Genomic Vision's technology in the United States.

"This new platform has the potential to enable us to develop new test services for improving clinical decisions involving of the care of patients at risk of developing several serious pathologies, such as hereditary breast cancer," **states Dr. Charles (Buck) Strom, Medical Director of Quest Diagnostics Nichols Institute.**

"We are very pleased to offer, on time, to our US partner the new genome analyzer. This achievement was made possible due to the strong involvement of our teams and I would like to thank all our employees that took part on this important challenge. Considering the strong experience of Quest Diagnostics in developing CLIA compliant tests, I'm very confident in their ability to continue the development work that will bring to physicians and patients a clinically important alternative to current genetic technologies," **concludes Aaron Bensimon, Genomic Vision's co-founder and Chairman.**

Next financial press release

- 2014 annual revenue, on January 15, 2015 (after market)

•••

ABOUT GENOMIC VISION

Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHelix FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

CONTACTS

Genomic Vision

Aaron Bensimon
Co-founder, Chairman & CEO
Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com

NewCap

Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr



DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.